Sinopharm Group (1099) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
26 Oct, 2026Executive summary
9M 2026 revenue was RMB427.61bn and net profit RMB8.08bn; revenue and net profit were below 9M 2025 levels.
Net profit attributable to equity holders of the parent was RMB5.31bn, compared with RMB5.31bn in 9M 2025.
Financial highlights
Operating profit was RMB10.78bn vs RMB10.87bn; total profit was RMB10.80bn vs RMB10.88bn in 9M 2025.
Operating revenue was RMB427.61bn vs RMB431.48bn; operating cost was RMB397.73bn vs RMB400.21bn.
Net profit was RMB8.08bn vs RMB8.10bn; parent-attributable net profit was RMB5.31bn vs RMB5.31bn.
Operating cash outflow was RMB23.93bn, improving from RMB39.08bn in 9M 2025.
Key financial ratios and metrics
Basic and diluted EPS were both RMB1.70 for 9M 2026 and 9M 2025.
Total assets were RMB407.87bn at 30 Sep 2026 vs RMB390.21bn at 31 Dec 2025; total liabilities were RMB268.60bn vs RMB255.86bn.
Consolidated equity was RMB139.27bn at 30 Sep 2026 vs RMB134.35bn at 31 Dec 2025.
Latest events from Sinopharm Group
- Revenue grew 8.05%, with lower expense ratios but weaker operating cash flow.1099
Q4 2023 - Revenue and profit declined, but retail pharmacy grew and cost controls improved margins.1099Q2 2026
- Revenue rose 1.23% but operating profit fell 20.41% year-over-year for Q1 2026.1099Q1 2026
- Net profit grew 3.94% to RMB 10.83 billion despite a 1.6% revenue decline, led by retail pharmacy gains.1099Q4 2025
- Revenue and profit fell, but operating cash flow and balance sheet improved.1099Q3 2025
- Revenue and profit declined, but retail pharmacy grew and expense ratios improved.1099Q2 2025
- Revenue and net profit declined year-over-year, with negative operating cash flow and rising liabilities.1099Q3 2024
- Revenue and profit fell, but digital transformation and liquidity remained strong.1099Q2 2024
- Net profit fell 22.14% as revenue declined and margin pressure persisted.1099Q4 2024